(GMED) Globus Medical - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 11.891m USD | Total Return: 34% in 12m

Spine Implants, Orthopedic Trauma, Joint Replacement, Robotic Surgery
Total Rating 69
Safety 94
Buy Signal 1.11
Medical Devices
Industry Rotation: -4.7
Market Cap: 11.9B
Avg Turnover: 88.4M USD
ATR: 3.15%
Peers RS (IBD): 85.5
Risk 5d forecast
Volatility33.5%
Rel. Tail Risk-15.8%
Reward TTM
Sharpe Ratio0.67
Alpha3.13
Character TTM
Beta0.844
Beta Downside0.650
Drawdowns 3y
Max DD44.40%
CAGR/Max DD0.39
EPS (Earnings per Share) EPS (Earnings per Share) of GMED over the last years for every Quarter: "2021-03": 0.49, "2021-06": 0.56, "2021-09": 0.5, "2021-12": 0.49, "2022-03": 0.42, "2022-06": 0.56, "2022-09": 0.5, "2022-12": 0.59, "2023-03": 0.53, "2023-06": 0.63, "2023-09": 0.57, "2023-12": 0.6, "2024-03": 0.72, "2024-06": 0.75, "2024-09": 0.83, "2024-12": 0.84, "2025-03": 0.68, "2025-06": 0.86, "2025-09": 1.18, "2025-12": 1.28,
EPS CAGR: 34.60%
EPS Trend: 91.5%
Last SUE: 0.89
Qual. Beats: 3
Revenue Revenue of GMED over the last years for every Quarter: 2021-03: 227.344, 2021-06: 251.016, 2021-09: 229.721, 2021-12: 250.021, 2022-03: 230.549, 2022-06: 263.648, 2022-09: 254.148, 2022-12: 274.498, 2023-03: 276.688, 2023-06: 291.615, 2023-09: 383.639, 2023-12: 616.534, 2024-03: 606.666, 2024-06: 629.691, 2024-09: 625.705, 2024-12: 657.293, 2025-03: 598.121, 2025-06: 745.342, 2025-09: 769.048, 2025-12: 826.389,
Rev. CAGR: 40.55%
Rev. Trend: 94.3%
Last SUE: 1.42
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

Watch

Description: GMED Globus Medical

Globus Medical, Inc. (GMED) develops and commercializes healthcare solutions for musculoskeletal disorders. The companys product portfolio includes spine products, orthopedic trauma solutions, and hip and knee arthroplasty solutions. The medical device sector is characterized by ongoing innovation and a focus on improving patient outcomes.

GMED also provides spinal cord stimulation and neuromonitoring services. Their technology offerings include the ExcelsiusGPS robotic guidance system and Surgimap surgical planning software. Medical technology companies often invest heavily in research and development to maintain a competitive edge.

The company distributes its products through direct sales, distributors, and independent sales agents. GMED was incorporated in 2003 and is based in Audubon, Pennsylvania. For a deeper dive into GMEDs financial performance and market position, continue your research on ValueRay.

Headlines to Watch Out For
  • Spine product sales drive revenue growth
  • Orthopedic trauma solutions expand market share
  • Robotic surgical platforms increase adoption rates
  • Healthcare spending trends impact device demand
  • Regulatory approvals influence product commercialization
Piotroski VR‑10 (Strict) 8.0
Net Income: 537.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.20 > 1.0
NWC/Revenue: 55.36% < 20% (prev 52.45%; Δ 2.92% < -1%)
CFO/TA 0.14 > 3% & CFO 753.4m > Net Income 537.9m
Net Debt (-407.5m) to EBITDA (817.1m): -0.50 < 3
Current Ratio: 4.26 > 1.5 & < 3
Outstanding Shares: last quarter (137.2m) vs 12m ago -1.78% < -2%
Gross Margin: 67.41% > 18% (prev 0.59%; Δ 6.68k% > 0.5%)
Asset Turnover: 55.69% > 50% (prev 47.97%; Δ 7.72% > 0%)
Interest Coverage Ratio: 250.9 > 6 (EBITDA TTM 817.1m / Interest Expense TTM 2.15m)
Altman Z'' 5.57
A: 0.31 (Total Current Assets 2.13b - Total Current Liabilities 498.5m) / Total Assets 5.30b
B: 0.26 (Retained Earnings 1.39b / Total Assets 5.30b)
C: 0.10 (EBIT TTM 538.9m / Avg Total Assets 5.28b)
D: 1.92 (Book Value of Equity 1.40b / Total Liabilities 729.5m)
Altman-Z'' Score: 5.57 = AAA
Beneish M -3.04
DSRI: 1.01 (Receivables 678.9m/578.3m, Revenue 2.94b/2.52b)
GMI: 0.87 (GM 67.41% / 58.90%)
AQI: 1.02 (AQ_t 0.48 / AQ_t-1 0.47)
SGI: 1.17 (Revenue 2.94b / 2.52b)
TATA: -0.04 (NI 537.9m - CFO 753.4m) / TA 5.30b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of GMED shares? As of April 09, 2026, the stock is trading at USD 91.96 with a total of 1,487,519 shares traded.
Over the past week, the price has changed by +4.81%, over one month by +4.73%, over three months by -2.81% and over the past year by +33.97%.
Is GMED a buy, sell or hold? Globus Medical has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy GMED.
  • StrongBuy: 4
  • Buy: 5
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the GMED price?
Analysts Target Price 110.1 19.7%
Globus Medical (GMED) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 22.4286
P/E Forward = 19.7239
P/S = 4.0462
P/B = 2.6002
P/EG = 1.4934
Revenue TTM = 2.94b USD
EBIT TTM = 538.9m USD
EBITDA TTM = 817.1m USD
Long Term Debt = 118.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.7m USD (from shortTermDebt, last quarter)
Debt = 118.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -407.5m USD (from netDebt column, last quarter)
Enterprise Value = 11.45b USD (11.89b + Debt 118.7m - CCE 557.2m)
Interest Coverage Ratio = 250.9 (Ebit TTM 538.9m / Interest Expense TTM 2.15m)
EV/FCF = 19.79x (Enterprise Value 11.45b / FCF TTM 578.8m)
FCF Yield = 5.05% (FCF TTM 578.8m / Enterprise Value 11.45b)
FCF Margin = 19.69% (FCF TTM 578.8m / Revenue TTM 2.94b)
Net Margin = 18.30% (Net Income TTM 537.9m / Revenue TTM 2.94b)
Gross Margin = 67.41% ((Revenue TTM 2.94b - Cost of Revenue TTM 957.8m) / Revenue TTM)
Gross Margin QoQ = 72.02% (prev 63.28%)
Tobins Q-Ratio = 2.16 (Enterprise Value 11.45b / Total Assets 5.30b)
Interest Expense / Debt = 1.23% (Interest Expense 1.46m / Debt 118.7m)
Taxrate = 19.21% (33.4m / 174.1m)
NOPAT = 435.4m (EBIT 538.9m * (1 - 19.21%))
Current Ratio = 4.26 (Total Current Assets 2.13b / Total Current Liabilities 498.5m)
Debt / Equity = 0.03 (Debt 118.7m / totalStockholderEquity, last quarter 4.57b)
Debt / EBITDA = -0.50 (Net Debt -407.5m / EBITDA 817.1m)
Debt / FCF = -0.70 (Net Debt -407.5m / FCF TTM 578.8m)
Total Stockholder Equity = 4.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.19% (Net Income 537.9m / Total Assets 5.30b)
RoE = 12.40% (Net Income TTM 537.9m / Total Stockholder Equity 4.34b)
RoCE = 12.09% (EBIT 538.9m / Capital Employed (Equity 4.34b + L.T.Debt 118.7m))
RoIC = 10.03% (NOPAT 435.4m / Invested Capital 4.34b)
WACC = 8.87% (E(11.89b)/V(12.01b) * Re(8.95%) + D(118.7m)/V(12.01b) * Rd(1.23%) * (1-Tc(0.19)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.65%
[DCF] Terminal Value 78.80% ; FCFF base≈509.3m ; Y1≈628.3m ; Y5≈1.07b
[DCF] Fair Price = 118.4 (EV 15.60b - Net Debt -407.5m = Equity 16.01b / Shares 135.3m; r=8.87% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 91.54 | EPS CAGR: 34.60% | SUE: 0.89 | # QB: 3
Revenue Correlation: 94.30 | Revenue CAGR: 40.55% | SUE: 1.42 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.06 | Chg7d=-0.005 | Chg30d=+0.030 | Revisions Net=+7 | Analysts=14
EPS current Year (2026-12-31): EPS=4.47 | Chg7d=+0.011 | Chg30d=+0.226 | Revisions Net=+13 | Growth EPS=+12.3% | Growth Revenue=+9.0%
EPS next Year (2027-12-31): EPS=4.96 | Chg7d=+0.041 | Chg30d=+0.275 | Revisions Net=+9 | Growth EPS=+10.8% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: +0.64 (9 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 8.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +2.0% (Analyst 6.5% - Implied 4.5%)
External Resources
Dataroma Stockcircle